Shots:

• Sanofi to acquire Kymab for $1.1B up front and ~$350M following the achievement of certain milestones. The transaction is expected to be completed in H1’21
• The acquisition will add KY1005 to Sanofi’s pipeline and will expedite its presence in the field of immunology
• Sanofi will get the global rights of KY1005 which is a mAb targeting OX40-ligand- currently being evaluated in early P-I/II study as monothx. and in combination with an anti-PD-L1 for immune-mediated diseases and inflammatory disorders

 ­ Ref: GlobeNewswire | Image: Kymab